Immunotherapy in NSCLC: A Promising and Revolutionary Weapon

Christian Rolfo(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Mauricio Mahave, Elisa Giovannetti(University of Pisa), Carolina Diaz Gallardo(Clínica Las Condes), Mariacarmela Santarpía(University of Messina), António Araújo, Patrick Pauwels(University of Antwerp), Christian Caglevic

Advances in experimental medicine and biology

January 1, 2017

10.1007/978-3-319-53156-4_5

Cited by 143

Related Papers

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

|The Lancet Oncology|2012|5.5k

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2019|3.3k

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

|New England Journal of Medicine|2009|2.4k

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2018|1.3k

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

|Journal of Thoracic Oncology|2018|661